We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
TRULICITY dulaglutide solution for injection 1.5 mg/0.5 mL prefilled pen (USA)
Section 19A approved medicine
TRULICITY dulaglutide solution for injection 1.5 mg/0.5 mL prefilled pen (USA)
Section 19A approval holder
Eli Lilly Australia Pty Ltd ABN 39 000 233 992
Phone
1800 454 559
Approved until
Status
Current
Medicines in short supply/unavailable
TRULICITY dulaglutide (rch) 1.5 mg/0.5 mL solution for injection prefilled pen - ARTG 217965
Indication(s)
Type 2 Diabetes Mellitus: glycaemic control
TRULICITY is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:
- As monotherapy.
- In combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see section 5.1 for data with respect to different combinations).
Type 2 Diabetes Mellitus: reduction in risk of major adverse cardiovascular events
TRULICITY is indicated as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have:
- established cardiovascular disease or
- multiple cardiovascular risk factors​
Images
